CAYA cancer patients in LMICs: a forward-looking observation of care and outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter observational study of CAYA cancer patients under active treatment or follow-up at participating LMIC hospitals. No experimental therapies or changes to standard care are involved; data are drawn from medical records and patient questionnaires about access to care and social factors. The goal is to describe treatment outcomes and the challenges families face during cancer care in LMIC settings. The study will help identify gaps in access, care delivery, and toxicity management to inform future improvements. Primary analyses will focus on real-world outcomes, treatment interruptions, and care-related barriers across sites.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Subjects must meet all the following criteria to be included in this study:

1. Age 0 to 21 years at study enrollment.
2. Diagnosed with cancer and receiving active treatment or undergoing follow-up at the participating sites.

   a. Note: Patients seen solely for consultation or diagnostic evaluations without subsequent treatment and those who have been off treatment for more than 5 years and are seen only for survivorship follow-up are not considered as meeting this criterion.
3. Willingness to provide informed consent/assent. For minors incapable of providing assent, or individuals unable to provide consent, consent must be obtained from a legal representative and in accordance with local requirements.

Exclusion Criteria:

Subjects meeting any of the following criteria must be excluded from this study:

1\. Any medical or psychological condition that, in the investigator's opinion, might compromise the ability of the patient to provide assent/informed consent/assent.

Where it's running

• Unidad Nacional de Oncología Pediátrica (UNOP)
  Guatemala City, Guatemala Recruiting
• Yeolyan Center for Cancer and Blood Disorders
  Yerevan, Armenia Not yet recruiting
• The Children's Cancer Hospital Egypt 57357
  Cairo, Egypt Not yet recruiting
• Fundación Ayúdame a Vivir
  San Salvador, El Salvador Not yet recruiting
• Hospital Mario Catarino Rivas
  San Pedro Sula, Honduras Not yet recruiting
• Hospital Escuela
  Tegucigalpa, Honduras Not yet recruiting

Study contacts

• Study coordinator: Gabriela Villanueva, MD.
• Email: gabriela.villanueva@resonancehealth.org
• Phone: +1-901-205-9518

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Child and Young Adult (CAYA) Cancer Outcomes Review

  This project looks at past treatment results to see what affects outcomes for children and young adults (ages 0–21) with leukemia and other cancers treated at participating centers in low- and middle-income countries.

  Recruiting at 5 sites Resonance, Inc. · Yerevan and 6 other locations · NCT07246213

• FaceSay: a computer program to help kids recognize facial expressions and improve social interactions

  A computer-based FaceSay program is tested to see if it helps survivors of pediatric brain tumors who have social difficulties see facial expressions better and relate more comfortably with peers.

  Recruiting Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT07923370

• Access to Innovative Cancer Treatments for Children and Young People in Belgium

  This observational study collects safety and effectiveness data on off‑label and compassionate cancer medicines used in kids and young adults up to age 25 in Belgium.

  Recruiting Universitaire Ziekenhuizen KU Leuven · Antwerp and 5 other locations · NCT07727694

• BCB-276 CAR T therapy for DIPG in children and young adults

  This study tests BCB-276, a patient's own CAR T cells against DIPG, after standard radiation, to see if it is safe and can help extend survival.

  Recruiting at 3 sites Phase 2 BrainChild Bio, Inc · Los Angeles, California and 5 other locations · NCT07680439

• First-in-human testing of 4A10 for relapsed or hard-to-treat ALL and lymphoblastic lymphoma

  This early-stage trial tests a new antibody therapy called 4A10 in patients with relapsed or hard-to-treat acute lymphoblastic leukemia or lymphoblastic lymphoma to see if it is safe and how the body handles it.

  Recruiting at 5 sites Phase 1 Allterum Therapeutics, Inc · Aurora, Colorado and 6 other locations · NCT07586618

• Virtual reality headsets to reduce anxiety and fear during intrathecal chemotherapy in children

  This project will try virtual reality headsets with children aged 4–10 who are receiving intrathecal chemotherapy to see if they reduce anxiety, fear, and changes in vital signs.

  Recruiting TC Erciyes University · Kayseri · NCT07537062

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.